Key Insights

Highlights

Treatment Research

2 treatments under study, led by Fosmanogepix

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

50%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Recruiting1
Unknown1

Clinical Trials (2)

Showing 2 of 2 trials
NCT06925321Phase 3RecruitingPrimary

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.

NCT04720144UnknownPrimary

Breakthrough Invasive Mold Infections Under Posaconazole Prophylaxis (BIMI)

Showing all 2 trials

Research Network

Common Treatments

  • Fosmanogepix1
  • Standard Of Care Antifungal Therapy1

Active Sponsors

  • Centre Hospitalier Universitaire Vaudois1
  • Basilea Pharmaceutica1
  • Basilea Pharmaceutica International AG Allschwil1
  • Biomedical Advanced Research and Development Authority1

Top Investigators

Related Conditions

  • Invasive Mold Infections Caused By Aspergillus Spp Fusarium Spp Lomentospora Prolificans Mucorales Fungi Or Other Multidrug Resistant Molds1
  • Breakthrough Invasive Mold Infections1
  • Hematologic Diseases1
  • Hematologic Malignancy1

Activity Timeline